Proniras Corporation is developing small-molecule therapeutics to treat seizures and brain injuries, specifically targeting substance use and specialty central nervous system disorders. Their current focus includes a novel medical countermeasure for opiate withdrawal, addressing critical gaps in treatment options for these conditions.
Funding
$8.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ALFounders
Product
Problem
Current treatment options for opiate withdrawal are limited and often inadequate, leaving a critical gap in addressing the complex physiological and psychological challenges associated with this condition. This lack of effective treatments contributes to relapse rates and hinders successful recovery.
Solution
Proniras Corporation is developing small-molecule therapeutics targeting substance use and specialty central nervous system (CNS) disorders, with a primary focus on a novel medical countermeasure for opiate withdrawal. Their approach aims to provide a more effective and targeted treatment option to alleviate the symptoms and challenges associated with opiate withdrawal. By developing novel small-molecule therapeutics, Proniras seeks to improve patient outcomes and address the unmet needs in the treatment of substance use disorders.
Target Audience
The primary target audience includes individuals undergoing opiate withdrawal, healthcare providers specializing in addiction treatment, and clinical researchers focused on substance use disorders.
Features
- Development of novel small-molecule therapeutics.
- Focus on substance use and specialty CNS disorders.
- Targeted treatment for opiate withdrawal.